Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Dual-Targeting PSMA And FRα Drug Conjugate Advances to U.S. Trial for Prostate Cancer June 18, 2026
- Phase 1 RIALTO Trial: Radiotherapy for Metastatic Prostate Cancer With Incomplete Hormone Response June 18, 2026
- Decipher Genomic Classifier Identifies Patients Who Benefit from Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer June 18, 2026
- CRISPR Advances June 16, 2026

EVM16: A Personalized mRNA Cancer Vaccine Enters Clinical Trials
/in Clinical Trial, Metastatic, Phase 1/by MaxNew Research Unlocks Potential for Immunotherapy in Prostate Cancer
/in Immunotherapy, Preclinical Research/by MaxIMGS-101: Phase 1/2 Clinical Trial Begins for Hypoxia-Reversing Agent in Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxSECuRE Trial Update: Promising Results in Metastatic Castration-Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 3 Trial: 225-Ac-PSMA-617 + ARPI vs SOC
/in Clinical Trial, Metastatic, Phase 3/by MaxFG-3246 Advances to Phase 2 Trial in Prostate Cancer After Promising Early Results
/in Clinical Trial, Metastatic, Phase 2/by MaxMacrophage-Drug Conjugates: A New Frontier in Cancer Treatment
/in Delivery, Preclinical Research/by MaxAndrogen Receptor Inhibition Enhances Immune Response in Prostate Cancer
/in Immunotherapy, Preclinical Research/by Max